Comparative Pharmacology
Head-to-head clinical analysis: FLUTICASONE PROPIONATE versus VANCERIL DOUBLE STRENGTH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUTICASONE PROPIONATE versus VANCERIL DOUBLE STRENGTH.
FLUTICASONE PROPIONATE vs VANCERIL DOUBLE STRENGTH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; binds to cytosolic glucocorticoid receptors, leading to inhibition of inflammatory mediators (e.g., cytokines, prostaglandins, leukotrienes) and suppression of immune cell activity.
Beclomethasone dipropionate is a corticosteroid with anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, reduced arachidonic acid release, and decreased synthesis of prostaglandins and leukotrienes. It also suppresses cytokine production, adhesion molecule expression, and eosinophil survival, thereby reducing airway inflammation.
Inhalation: 88-440 mcg twice daily for asthma (DPI: 100-500 mcg twice daily; HFA: 44-220 mcg twice daily). Intranasal: 2 sprays (50 mcg/spray) per nostril once daily (total 200 mcg/day). Topical: Apply thin layer to affected area 1-2 times daily.
2 inhalations (168 mcg beclomethasone dipropionate) twice daily via oral inhalation.
None Documented
None Documented
Clinical Note
moderateFluticasone propionate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Gatifloxacin."
Clinical Note
moderateFluticasone propionate + Rosoxacin
"The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Rosoxacin."
Clinical Note
moderateFluticasone propionate + Levofloxacin
"The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life is approximately 7.8 hours after intravenous administration; extends to 10-14 hours following intranasal or inhaled routes due to slow absorption from the lung/nasal mucosa.
Terminal elimination half-life: 1.5–2 hours for beclomethasone dipropionate; 2.7 hours for active metabolite beclomethasone-17-monopropionate. Clinical context: supports twice-daily dosing.
Primarily hepatic metabolism via CYP3A4 to inactive metabolites; <5% excreted unchanged in urine; biliary/fecal elimination accounts for >90% of metabolites.
Primarily hepatic metabolism; metabolites excreted renally (~90% as free and conjugated metabolites) and fecally (<10%).
Category A/B
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid
Fluticasone propionate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Trovafloxacin."